Haizheng Pharmaceutical announced that in the first three quarters of 2026, it is expected to achieve operating income of about 6.52 billion yuan, down 17.71% year on year; net profit attributable to shareholders of listed companies is expected to be about 1.15 billion yuan, an increase of about 149.46% year on year; net profit after deducting non-recurring profit and loss is expected to be about 980 million yuan, an increase of about 99.59% year on year. The decline in revenue was mainly due to the completion of the 100% equity transfer of Zhejiang Pharmaceutical Industry Co., Ltd. and the company's announcement. After excluding this impact, revenue increased by about 7.16% year-on-year. The increase in performance was mainly due to increased sales of innovative drugs and pet drugs, release of production scale effects, and product structure optimization, etc. The increase in non-recurring profit and loss was mainly due to the above equity transfer and disposal proceeds.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.